Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients
Conditions
Previous Treated Metastatic Non-small Cell Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung
Conditions: Keywords
Pemetrexed, Gefitinib, iressa, alimta
Study Type
Interventional
Study Phase
Phase 2
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Gefitinib Type: Drug
Name: Pemetrexed Type: Drug
Overall Status
Recruiting
Summary
To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Cells pathologically diagnosed as histological or radical surgery or radiation therapy is not possible stage IIIB and stage IV non-small-cell lung cancer patients

- second line

- ECOG 0~2

- Patients with normal liver function and renal function

Exclusion Criteria:

- Patients with severe acute infection requiring antibiotic therapy

- Patients who have received treatment in other areas of cancer within 5 years

- During pregnancy and lactation patients
Location
Gachon university Gil Medical Center
Incheon, Korea, Republic of
Status: Recruiting
Contact: HeeKyung Ahn, professor - +82-32-460-2625 - hkahn@gilhospital.com
Start Date
February 2008
Completion Date
December 2013
Sponsors
Gachon University Gil Medical Center
Source
Gachon University Gil Medical Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page